ISRG Intuitive Surgical (ISRG) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001035267
Congress · 1Form 144 · 9
Insider buyers, 180 days
0
Funds added, last quarter
1,092
13F, latest reported quarter
Conversions, 180 days
28
Codes C/M, not in net · $1.6M priced
What the filings say about ISRG
Insiders, 180 days
-$19.7M net sold
8 sellers · 41% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-01-30
Planned sales (Form 144), 90 days
$24.6M
9 notices
Intuitive Surgical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, INTUITIVE SURGICAL INC insiders sold a net $19.7M of stock across 417 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Aug 11, 2026.
- The trade is 1.7% of the 1,204,530 shares held after it.
- 3 other insiders sold within 30 days.
- 1,092 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GUTHART GARY S sold about $9.1M of ISRG under a 10b5-1 plan on Oct 23, 2026; 3 other insiders sold within 30 days and 1,092 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 27, 2026.
- 3 other insiders sold within 30 days.
- 1,092 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP Chief Human Resources Offi WADORS PATRICIA L sold about $478.4K of ISRG under a 10b5-1 plan on Oct 23, 2026; 3 other insiders sold within 30 days and 1,092 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 15, 2026.
- The trade is 394.4% of the 1,026 shares held after it.
- 3 other insiders sold within 30 days.
- 1,092 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP Corporate Controller Widman Fredrik sold about $1.8M of ISRG under a 10b5-1 plan on Oct 23, 2026; 3 other insiders sold within 30 days and 1,092 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Nov 12, 2025.
- 3 other insiders sold within 30 days.
- 1,092 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BARRATT CRAIG H sold about $510.4K of ISRG under a 10b5-1 plan on Oct 23, 2026; 3 other insiders sold within 30 days and 1,092 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Mar 3, 2026.
- The trade is 53.2% of the 1,026 shares held after it.
- 1 other insider sold within 30 days.
- 1,092 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP Corporate Controller Widman Fredrik sold about $204.4K of ISRG under a 10b5-1 plan on Sep 15, 2026; 1 other insider sold within 30 days and 1,092 funds added in the latest 13F quarter.417 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$19.7M over 180 days
-$16.9M over 90 days
below 92% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
1,092 funds bought in last quarter
more than 99% of Medical Devices
Revenue
+20.5% year over year
more than 74% of Medical Devices
Margin
28.4% net margin
more than 97% of Medical Devices
Buybacks
$4.4B repurchased, FY to 2026-09-30
the highest in Medical Devices
Short interest
2.1% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
below 62% of Medical Devices
What changed in the last 30 days
Oct 26Director GUTHART GARY S sold $9.1M under a 10b5-1 plan (Oct 23)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 26VP Corporate Controller Widman Fredrik sold $1.8M under a 10b5-1 plan (Oct 23)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 23Director GUTHART FAMILY TRUST filed to sell $12.0M by Oct 23 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 23Officer FREDRIK WIDMAN filed to sell $2.3M by Oct 23 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 23Director Craig H. Barratt filed to sell $510.4K by Oct 23 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ISRG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-14.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ISRG: institutional holders (13F)
13F holdings, latest reported quarter
30,024,648 sh
$11.9B
23,131,099 sh
$9.2B
16,063,040 sh
$6.4B
11,843,563 sh
$4.7B
8,534,767 sh
$3.4B
Congress trades in ISRG
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-01-30 · disclosed 14 days later
$1,001 - $15,000
Bought 2025-12-10 · disclosed 33 days later
$1,001 - $15,000
Bought 2025-11-18 · disclosed 27 days later
$1,001 - $15,000
Sold 2025-09-03 · disclosed 42 days later
$1,001 - $15,000
Sold 2025-07-16 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ISRG planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Craig H. Barratt
Filed 2026-10-23
$510.4K
GUTHART FAMILY TRUST
Filed 2026-10-23
$12.0M
PATRICIA WADORS
Filed 2026-10-23
$478.5K
FREDRIK WIDMAN
Filed 2026-10-23
$2.3M
FREDRIK WIDMAN
Filed 2026-09-15
$823.2K
ISRG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares U.S. Medical Devices ETF
$456.3M position · as of 2026-06-30
15.1%
Biondo Focus Fund
$5.4M position · as of 2026-06-30
11.9%
Select Medical Technology and Devices Portfolio
$221.9M position · as of 2026-05-31
7.5%
Global X Robotics & Artificial Intelligence ETF
$230.0M position · as of 2026-05-31
6.1%
INVESTMENT HOUSE GROWTH FUND (THE)
$9.5M position · as of 2026-07-31
4.2%
Putnam Global Health Care Fund
$59.2M position · as of 2026-05-31
4.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
48 registered trials, 18 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
0 active
2
Phase 3
1 active
1
Phase 4
1 active
43
Not applicable
16 active
What changed recently
Retrospective Acute Care Appendectomy Study
2026-09-25 · Recruiting → Active Not Recruiting
,
A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedure
2026-09-05 · Completion moved 2026-08 → 2026-08-19
,
A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedure
2026-09-05 · Recruiting → Active Not Recruiting
,
A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing
2026-09-03 · Not Yet Recruiting → Recruiting
Phase 4
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Intuitive Surgical Inc Pac
Cycle 2026 · $0K spent
$0
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Dr.Guthart
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$18.2M
$42.6M
$8.4M
+165%
+4%
2023
$12.4M
$22.7M
$6.9M
+71%
-1%
2022
$10.3M
$1.6M
$5.0M
+35%
+5%
2021
$8.1M
$17.5M
$4.5M
+82%
+37%
2020
$6.0M
$15.0M
$3.5M
+38%
+33%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $19.7M sold by insiders over 180 days, 1,092 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $24.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ISRG financials
Revenue growth
+20.5%
XBRL, annual
Net margin
28.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$11.6B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM ISRG
| FY Dec 2025 | $10.1B |
| FY Dec 2024 | $8.4B |
| FY Dec 2023 | $7.1B |
| FY Dec 2022 | $6.2B |
| FY Dec 2021 | $5.7B |
| Sep 2026 | $3.0B |
| Jun 2026 | $2.9B |
| Mar 2026 | $2.8B |
| Dec 2025 | $2.9B |
| Sep 2025 | $2.5B |
| Jun 2025 | $2.4B |
| Mar 2025 | $2.3B |
| Dec 2024 | $2.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+25.5%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM ISRG
| FY Dec 2025 | +28.4% |
| FY Dec 2024 | +27.8% |
| FY Dec 2023 | +25.2% |
| FY Dec 2022 | +21.3% |
| FY Dec 2021 | +29.9% |
| Sep 2026 | +17.1% |
| Jun 2026 | +28.3% |
| Mar 2026 | +29.6% |
| Dec 2025 | +27.7% |
| Sep 2025 | +28.1% |
| Jun 2025 | +27.0% |
| Mar 2025 | +31.0% |
| Dec 2024 | +28.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.6B
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM ISRG
| FY Dec 2025 | $2.5B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $749.6M |
| FY Dec 2022 | $958.4M |
| FY Dec 2021 | $1.7B |
| Sep 2026 | $1.1B |
| Jun 2026 | $948.4M |
| Mar 2026 | $808.6M |
| Dec 2025 | $730.0M |
| Sep 2025 | $735.6M |
| Jun 2025 | $560.1M |
| Mar 2025 | $465.0M |
| Dec 2024 | $510.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity ISRG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt ISRG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+18.0%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity ISRG
| FY Dec 2025 | +16.7% |
| FY Dec 2024 | +15.6% |
| FY Dec 2023 | +14.8% |
| FY Dec 2022 | +11.5% |
| FY Dec 2021 | +15.8% |
| Sep 2026 | +18.0% |
| Jun 2026 | +17.4% |
| Mar 2026 | +17.2% |
| Dec 2025 | +16.7% |
| Sep 2025 | +16.9% |
| Jun 2025 | +16.0% |
| Mar 2025 | +15.9% |
| Dec 2024 | +15.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+15.3%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets ISRG
| FY Dec 2025 | +14.6% |
| FY Dec 2024 | +13.6% |
| FY Dec 2023 | +12.7% |
| FY Dec 2022 | +10.0% |
| FY Dec 2021 | +13.8% |
| Sep 2026 | +15.3% |
| Jun 2026 | +15.3% |
| Mar 2026 | +15.1% |
| Dec 2025 | +14.6% |
| Sep 2025 | +14.8% |
| Jun 2025 | +14.2% |
| Mar 2025 | +14.1% |
| Dec 2024 | +13.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital ISRG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+19.1%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
Return on capital employed ISRG
| FY Dec 2025 | +16.6% |
| FY Dec 2024 | +15.3% |
| FY Dec 2023 | +13.9% |
| FY Dec 2022 | +13.2% |
| FY Dec 2021 | +16.1% |
| Sep 2026 | +19.1% |
| Jun 2026 | +18.4% |
| Mar 2026 | +18.0% |
| Dec 2025 | +16.6% |
| Sep 2025 | +16.8% |
| Jun 2025 | +15.7% |
| Mar 2025 | +15.3% |
| Dec 2024 | +15.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
54.76x
close 2026-10-23 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
P/E, trailing ISRG
| FY Dec 2025 | 71.87x |
| FY Dec 2024 | 81.30x |
| FY Dec 2023 | 67.07x |
| FY Dec 2022 | 72.50x |
| FY Dec 2021 | 77.10x |
| Sep 2026 | 49.23x |
| Jun 2026 | 45.61x |
| Mar 2026 | 55.95x |
| Dec 2025 | 71.87x |
| Sep 2025 | 59.08x |
| Jun 2025 | 75.68x |
| Mar 2025 | 72.51x |
| Dec 2024 | 81.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value ISRG
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield ISRG
| FY Dec 2025 | +1.2% |
| FY Dec 2024 | +0.7% |
| FY Dec 2023 | +0.6% |
| FY Dec 2022 | +1.0% |
| FY Dec 2021 | +1.4% |
| Sep 2026 | +2.5% |
| Jun 2026 | +2.3% |
| Mar 2026 | +1.7% |
| Dec 2025 | +1.2% |
| Sep 2025 | +1.4% |
| Jun 2025 | +1.0% |
| Mar 2025 | +1.0% |
| Dec 2024 | +0.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
6.01x
P/E over trailing EPS growth of 9%: four quarters to 2026-09-30 against the four to 2025-09-30
PEG, trailing ISRG
| FY Dec 2025 | 3.16x |
| FY Dec 2024 | 2.94x |
| FY Dec 2023 | 1.79x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Sep 2026 | 5.40x |
| Jun 2026 | 2.13x |
| Mar 2026 | 2.71x |
| Dec 2025 | 3.16x |
| Sep 2025 | 2.72x |
| Jun 2025 | 3.24x |
| Mar 2025 | 3.11x |
| Dec 2024 | 2.94x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $10.1B | $8.4B | $7.1B | $6.2B |
| Gross profit | $6.6B | $5.6B | $4.7B | $4.2B |
| Operating income | $2.9B | $2.3B | $1.8B | $1.6B |
| Net income | $2.9B | $2.3B | $1.8B | $1.3B |
| EPS (diluted) | 7.87 | 6.42 | 5.03 | 3.65 |
| Operating cash flow | $3.0B | $2.4B | $1.8B | $1.5B |
| Cash | $3.4B | $2.0B | $2.8B | $1.6B |
| Buybacks | $2.3B | $0 | $416.3M | $2.6B |
SEC XBRL, fiscal years, as known on 2026-10-27
ISRG Stock Sonar score 5/7 axes
Find similar shapesCompareISRG ranks highest on profitability (92nd percentile) and institutional and government (83rd), and lowest on insider conviction (8th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ISRG filings, in plain words
Are Intuitive Surgical insiders buying or selling ISRG?
In the 180 days to 2026-10-27, Intuitive Surgical insiders were net sellers, a net $19.7M across purchases and sales reported on Form 4, by 8 sellers.
Have members of Congress traded ISRG?
Yes. In the year to 2026-10-27, 1 House member disclosed buying ISRG and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-01-30.
Are there planned insider sales of ISRG?
Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $24.6M of stock; the latest, by Craig H. Barratt, was filed 2026-10-23.
Read the full summary
In the 180 days to 2026-10-27, Intuitive Surgical insiders were net sellers of ISRG, a net $19.7M across purchases and sales reported on Form 4 by 8 sellers. 41% of the 37 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying ISRG and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-01-30. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $24.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
